EGFR and neoplasm: In contrast, the third-generation Osimertinib, a mono-anilino pyrimidine compound, has demonstrated sustained CNS activity and the ability to inhibit tumor growth selectively, making it an attractive option for the treatment of EGFR-Fused NSCLC [188].